Mizuho restated their buy rating on shares of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) in a research report report published on Wednesday morning. They currently have a $32.00 price objective on the biopharmaceutical company’s stock.

Several other equities research analysts also recently commented on the company. Zacks Investment Research raised Alder BioPharmaceuticals from a hold rating to a buy rating and set a $13.00 target price on the stock in a report on Tuesday, July 11th. Royal Bank Of Canada started coverage on Alder BioPharmaceuticals in a report on Thursday, September 14th. They set an outperform rating and a $17.00 price target on the stock. Credit Suisse Group set a $11.00 price target on Alder BioPharmaceuticals and gave the company a hold rating in a report on Thursday, August 24th. BidaskClub raised Alder BioPharmaceuticals from a strong sell rating to a sell rating in a report on Friday, August 25th. Finally, Needham & Company LLC set a $36.00 price target on Alder BioPharmaceuticals and gave the company a buy rating in a report on Monday, July 17th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $28.07.

Shares of Alder BioPharmaceuticals (ALDR) opened at $11.15 on Wednesday. Alder BioPharmaceuticals has a 1-year low of $8.60 and a 1-year high of $34.30.

Alder BioPharmaceuticals (NASDAQ:ALDR) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.21) by $0.29. During the same period in the prior year, the company earned ($0.70) earnings per share. sell-side analysts anticipate that Alder BioPharmaceuticals will post -5.36 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Alder BioPharmaceuticals, Inc. (ALDR) Rating Reiterated by Mizuho” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/12/alder-biopharmaceuticals-inc-aldr-rating-reiterated-by-mizuho.html.

In related news, insider Mark James Litton sold 16,520 shares of the company’s stock in a transaction on Monday, October 16th. The stock was sold at an average price of $12.33, for a total transaction of $203,691.60. Following the completion of the sale, the insider now owns 116,452 shares in the company, valued at $1,435,853.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 10.60% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in Alder BioPharmaceuticals by 5.5% during the second quarter. Vanguard Group Inc. now owns 3,626,573 shares of the biopharmaceutical company’s stock valued at $41,525,000 after acquiring an additional 187,871 shares during the last quarter. Janus Henderson Group PLC purchased a new stake in Alder BioPharmaceuticals during the second quarter valued at $36,956,000. Redmile Group LLC increased its position in Alder BioPharmaceuticals by 16.4% during the second quarter. Redmile Group LLC now owns 2,223,811 shares of the biopharmaceutical company’s stock valued at $25,463,000 after acquiring an additional 313,925 shares during the last quarter. State Street Corp increased its position in Alder BioPharmaceuticals by 9.4% during the second quarter. State Street Corp now owns 1,944,755 shares of the biopharmaceutical company’s stock valued at $22,267,000 after acquiring an additional 167,642 shares during the last quarter. Finally, BB Biotech AG increased its position in Alder BioPharmaceuticals by 15.2% during the second quarter. BB Biotech AG now owns 1,941,008 shares of the biopharmaceutical company’s stock valued at $22,225,000 after acquiring an additional 255,858 shares during the last quarter. Institutional investors own 78.57% of the company’s stock.

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Analyst Recommendations for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Stock Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related stocks with our FREE daily email newsletter.